Global Liquid Biopsy Market Size To Worth USD 25.24 Billion By 2032 | CAGR of 11.5%
SPHERICAL INSIGHTS LLP
8 min read
SPHERICAL INSIGHTS LLP
The Liquid Biopsy Market Size was valued at USD 8.50 Billion in 2022 and the Worldwide liquid biopsy market Size is expected to reach USD 25.24 Billion By 2032, according to a research report published by Spherical Insights & Consulting. Companies Covered: Bio-Rad Laboratories, Biocept Inc., Guardant Health, Illumina, Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Laboratory Corporation of America Holdings, MDxHealth SA, QIAGEN N.V, Thermo Fisher Scientific Inc., and Other key venders.
New York, United States, Nov. 15, 2023 (GLOBE NEWSWIRE) -- The Global Liquid Biopsy Market Size is expected to reach USD 25.24 Billion By 2032, at a CAGR of 11.5% during the forecast period 2022 to 2032.
Liquid biopsy is a ground breaking non-invasive medical procedure that allows for early cancer identification and monitoring by analyzing numerous biomarkers found in a patient's blood or other bodily fluids. In contrast to conventional tissue biopsies, which can be invasive and limited by tumor accessibility, liquid biopsy provides a less hazardous and more accessible method of getting critical genetic and molecular information about tumors. Liquid biopsy gives information on a tumor's genetic mutations, therapy response, and potential for metastasis by identifying circulating tumor cells (CTCs), cell-free DNA (cfDNA), exosomes, and other biomolecules.
Browse key industry insights spread across 200 pages with 120 Market data tables and figures & charts from the report onthe “Global Liquid Biopsy Market Size, Share, and COVID-19 Impact Analysis,By Technology (NGS, PCR, FISH, and Others), By Workflow (Sample Preparation, Library Preparation, Sequencing, and Data Analysis), By Usage (RUO and Clinical), By Types of Sample (Blood, Urine, Saliva, and Cerebrospinal Fluid), By Circulating Biomarker (Circulating Tumor Cells, Cell-free DNA, Circulating Cell-Free RNA, Exosomes & Extracellular Vesicles, and Others), By Products (Test/Services, Kits & Consumable, and Instruments), By Indication Type (Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Melanoma, and Others), By Clinical Application (Treatment Monitoring, Prognosis & Recurrence Monitoring, Treatment Selection, and Diagnosis & Screening),By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2022 – 2032.”
In 2022, the NGS segment accounted for around 52.8% market share On the basis of the technology, the global liquid biopsy market is segmented into NGS, PCR, FISH, and others. The NGS (Next-Generation Sequencing) segment has held the largest market share in the liquid biopsy market due to its exceptional capabilities in detecting and analyzing genetic mutations and alterations. NGS offers high-throughput sequencing of circulating tumor DNA and other biomarkers, providing precise and comprehensive insights into cancer profiles. Its ability to handle multiple samples simultaneously and rapidly generate large amounts of genomic data has made NGS the preferred choice for liquid biopsy testing.
The blood segment held the largest market over the forecast period Based on the sample type, the global liquid biopsy market is segmented into blood, urine, saliva, and cerebrospinal fluid. The blood segment dominated the liquid biopsy market over the forecast period primarily due to its non-invasive nature and ease of sample collection. Blood-based liquid biopsies offer a convenient and accessible method to detect and analyze circulating tumor cells (CTCs) and cell-free DNA (cfDNA), providing valuable information about cancer progression, treatment response, and genetic mutations.
The lung cancer segment held the largest revenue share of around 31.6% in 2022. Based on the indication, the global liquid biopsy market is segmented into lung cancer, breast cancer, prostate cancer, colorectal cancer, melanoma, and others. The lung cancer segment held the largest share in the liquid biopsy market owing to the high incidence and prevalence of lung cancer globally. Liquid biopsy offers a non-invasive and repeatable method for early detection, monitoring, and assessment of treatment response in lung cancer patients. The ability to analyze circulating tumor
The cell-free DNA segment is expected to grow at a significant CAGR of around 11.6% during the forecast period Based on the circulating biomarker, the global liquid biopsy market is segmented into circulating tumor cells, cell-free DNA, circulating cell-free RNA, exosomes & extracellular vesicles, and others. The cell-free DNA (cfDNA) segment is anticipated to witness substantial growth in the liquid biopsy market due to its remarkable potential in cancer diagnosis and monitoring. cfDNA-based liquid biopsies allow the detection of tumor-specific genetic mutations and alterations, offering a non-invasive and real-time approach to track cancer progression and treatment response.
Asia-Pacific is predicted to grow at a fastest CAGR of around 11.7% over the projected period.
Based on region, Asia-Pacific is expected to experience the fastest growth in the liquid biopsy market during the forecast period, due to the rising prevalence of cancer, along with an aging population, which creates a significant demand for early detection and accurate monitoring solutions. Increasing investments in healthcare infrastructure and research capabilities have facilitated the adoption of advanced medical technologies, including liquid biopsy. North America has emerged as a dominant player in the liquid biopsy market, holding the largest market share. The region benefits from a robust healthcare infrastructure and a high level of awareness about the importance of early cancer detection and personalized medicine. Significant investments in research and development, along with the presence of major biotechnology and pharmaceutical companies, have fostered the advancement of liquid biopsy technologies. Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the global market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market. Major players in the global liquid biopsy market include Bio-Rad Laboratories, Biocept Inc., Guardant Health, Illumina, Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Laboratory Corporation of America Holdings, MDxHealth SA, QIAGEN N.V., and Thermo Fisher Scientific Inc. And Other Key Vendors.
In July 2022, Nanostics Inc. announced the start of its validation study for its ClarityDX diagnostic platform clinical research, which is a noninvasive liquid biopsy test for bladder cancer.
In June 2021, Biocept Inc. and Quest Diagnostics cooperated to create a cutting-edge NGS diagnostic technique for lung cancer patients.
Market Segment This study forecasts revenue at global, regional, and country levels from 2019 to 2032. Spherical Insights has segmented the global liquid biopsy market based on the below-mentioned segments:
Liquid Biopsy Market, By Technology
NGS
PCR
FISH
Others
Liquid Biopsy Market, By Workflow
Sample Preparation
Library Preparation
Sequencing
Data Analysis
Liquid Biopsy Market, By Usage
RUO
Clinical
Liquid Biopsy Market, By Type of Sample
Blood
Urine
Saliva
Cerebrospinal Fluid
Liquid Biopsy Market, By Circulating Biomarker
Circulating Tumor Cells
Cell-free DNA
Circulating Cell-Free RNA
Exosomes & Extracellular Vesicles
Others
Liquid Biopsy Market, By Products
Test/Services
Kits & Consumable
Instruments
Liquid Biopsy Market, By Indication Type
Lung Cancer
Breast Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Others
Liquid Biopsy Market, By Clinical Application
Treatment Monitoring
Prognosis & Recurrence Monitoring
Treatment Selection
Diagnosis & Screening
Liquid Biopsy Market, Regional Analysis
North America
US
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
Australia
Rest of Asia Pacific
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
UAE
Saudi Arabia
Qatar
South Africa
Rest of Middle East & Africa
Browse Related Reports
Global Stoma Care Market Size, Share, and COVID-19 Impact Analysis, By Product Type (Product Type (Ostomy Bags {One-piece Bags, Two-piece Bags}, Accessories, Others), By Surgery Type (Colostomy, Ileostomy, Urostomy), By End-use (Hospitals & Specialty Clinics, ASCs, Home Care Settings, Others), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2022 – 2032
Global Cleanroom Technologies Market Size, Share, and COVID-19 Impact Analysis, By Product (Equipment - Fan Filter, HVAC, Vacuum Systems; Consumable - Safety, Disinfectants), Type (Standard Modular (Hardwall, Softwall), Mobile), By End User (Pharmaceutical Industry, Biotechnology Industry, Medical Device Manufacturers, Semiconductor, Food & Beverages), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2022 – 2032
Global Protein Labeling Market Size, By Product Type (Reagents, Kits, Services), By Labeling Method (In-vitro Labeling Methods, In-vivo Labeling Methods), By Application (Cell-based Assays, Fluorescence Microscopy, Immunological Techniques, Protein Microarray, Mass Spectrometry, Others), By End-user (Hospitals & Clinics, Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Others), By Geographic Scope and Forecast, 2023 – 2032
United States Orthopedic Devices Market Size, Share, and COVID-19 Impact Analysis, By Product (Fixation, Replacement Devices, Braces, Spinal Implants, Arthroscopy, Orthobiolgics), By Application (Hip, Knee, Spine, Cranio-Maxillofacial, Sports, Medical Extremities & Trauma), By End User (Hospitals, Orthopedic Clinic, Ambulatory Surgical Centers, and Others), and United States Orthopedic Devices Market Insights, Industry Trend, Forecasts to 2032
About the Spherical Insights & Consulting
Spherical Insights& Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
